Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health : 2019 Letter to Shareholders

11/24/2019 | 05:38pm EDT

Access to this site

Your access to the site constitutes your agreement to be bound by the General Conditions which are available at http://www.asx.com.au/legal/general_conditions.htm.

Real time company announcements are freely available on our site for investors' private and personal use. A distinction is drawn however where use is for a 'commercial' as opposed to 'private or personal' purpose. Should you wish to access and use this information for a commercial purpose, the express written authority of ASX is required.

Professional or commercial use would include use by any person that falls into the following categories:

  • You are seeking to access and use the information other than for private or personal investment purposes.
  • You are seeking to access and use the information in connection with any trade or business.
  • You are engaged in the business of accessing or aggregating information and redistributing or otherwise furnishing that information to third parties.
  • You are a member or participating organisation of an exchange or an approved representative or other employee of such an organisation accessing and using the information in connection with your employment, or any associated person of the foregoing.
  • You are employed by a bank, insurance company, fund or asset manager or other organisation to perform functions related to trading or investment in financial products and you are accessing and using the information in connection with your employment.

If you are unsure as to whether you come within one of the above categories, please email your query to info@asx.com.au.

ASX provides ASX ComNews and ASX ComNews Direct with additional features to support professional investors and other commercial activities. Further information on these products can be obtained by emailing info@asx.com.au.

Company announcements and related materials made available through this site may contain embedded hyperlinks to external websites operated by third parties or their licensees or contractors ('Third Party Websites'). Third Party Websites are not under the control of ASX, and ASX is not responsible for the content of any Third Party Website. ASX does not endorse, sponsor or approve of any of the products or services provided through the Third Party Websites, or the owners or operators of such Third Party Websites. ASX does not represent or warrant the quality, reliability, accuracy or completeness of any content of the Third Party Websites, nor does ASX represent or warrant that any Third Party Website will be free of computer viruses or other conditions which could damage or interfere with your computer system, data or software. Neither ASX nor its directors, officers, agents, employees or contractors will be liable for any loss or damage arising in any way (including negligence) from or in connection with your access to and use of a Third Party Website and any such access or use is done solely at your own risk.

I confirm that any content I access will not be used for any commercial purpose in the context as explained above, without the express written authority of ASX.


ResApp Health Limited published this content on 25 November 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 November 2019 22:37:03 UTC

ę Publicnow 2019
06/03RESAPP HEALTHá : Medgate extends European ResAppDx trial
05/17RESAPP HEALTHá : Recruits First Participant in COVID-19 Study; Shares Jump 6%
05/04RESAPP HEALTHá : Signs Distribution Deal for Smartphone Diagnostic App in Kenya;..
05/03RESAPP HEALTHá : Agreement secured with Ilara Health to sell ResAppDx in Kenya
04/12RESAPP HEALTHá : Raises Over $4 Million in Placement
04/11RESAPP HEALTHá : secures firm commitments to raise $5.5 million
03/24RESAPP HEALTHá : Secures Regulatory Clearance in Australia for Wearable Medical ..
03/24RESAPP HEALTHá : TGA clearance achieved for wearable
03/11RESAPP HEALTHá : Grants AstraZeneca License for Cough Counting Tech for Asthma P..
03/10RESAPP HEALTHá : to Conduct Study to Develop Smartphone-Based COVID-19 Screening..
More news
Sales 2020 - - -
Net income 2020 -8,47 M -6,52 M -6,52 M
Net cash 2020 5,45 M 4,20 M 4,20 M
P/E ratio 2020 -14,6x
Yield 2020 -
Capitalization 40,4 M 31,1 M 31,1 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 500
Free-Float 95,7%
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus -
Number of Analysts
Average target price
Last Close Price 0,05 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Roger Aston Non-Executive Chairman
Udantha Abeyratne Chief Scientist
Rob Keniger Vice President-Technology
Christopher Ntoumenopoulos Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SAP SE12.16%172 030
INTUIT INC.25.57%128 623
SERVICENOW, INC.-8.18%99 796
DOCUSIGN, INC.12.68%48 802